These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36682470)

  • 41. Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin.
    Stutz L; Halter JP; Heim D; Passweg JR; Medinger M
    Bone Marrow Transplant; 2022 Mar; 57(3):391-398. PubMed ID: 34980902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.
    Aldoss I; Yang D; Malki MMA; Mei M; Mokhtari S; Artz A; Cao T; Salhotra A; Ali H; Aribi A; Khaled S; Arslan S; Sandhu K; Koller P; Mansour J; Spielberger R; Stein A; Snyder D; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
    Transplant Cell Ther; 2021 Mar; 27(3):255.e1-255.e9. PubMed ID: 33781525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
    Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
    Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Sabatino D; Henneman A; Ahmad S; Jou E; Goldberg B
    J Oncol Pharm Pract; 2023 Jun; 29(4):840-845. PubMed ID: 35293248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell Transplantation (HCT).
    Putta S; Young B; Pine P; Shi J; Amber V; Saber W; Levine JE; Grupp SA
    Transplant Cell Ther; 2024 Oct; 30(10):986.e1-986.e7. PubMed ID: 38996974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab.
    Wudhikarn K; King AC; Geyer MB; Roshal M; Bernal Y; Gyurkocza B; Perales MA; Park JH
    Blood Adv; 2022 Mar; 6(5):1432-1443. PubMed ID: 35042232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.
    Putta S; Young BA; Levine JE; Reshef R; Nakamura R; Strouse C; Perales MA; Howard A; Pine P; Shi J; Zhang P; Ho VT; Saber W
    Transplant Cell Ther; 2023 Mar; 29(3):166.e1-166.e10. PubMed ID: 36574581
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.
    Mohty M; Battista ML; Blaise D; Calore E; Cesaro S; Maximova N; Perruccio K; Renard C; Wynn R; Zecca M; Labopin M; Hanvesakul R; Amber V; Ryan RJ; Lawson S; Ciceri F
    Bone Marrow Transplant; 2021 Oct; 56(10):2454-2463. PubMed ID: 34059801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.
    Coutsouvelis J; Kirkpatrick CM; Dooley M; Spencer A; Kennedy G; Chau M; Huang G; Doocey R; Copeland TS; Do L; Bardy P; Kerridge I; Cole T; Fraser C; Perera T; Larsen SR; Mason K; O'Brien TA; Shaw PJ; Teague L; Butler A; Watson AM; Ramachandran S; Marsh J; Khan Z; Hamad N
    Transplant Cell Ther; 2023 Jun; 29(6):383.e1-383.e10. PubMed ID: 36934993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Kantarjian HM; Boissel N; Papayannidis C; Luskin MR; Stelljes M; Advani AS; Jabbour EJ; Ribera JM; Marks DI
    Cancer; 2024 Nov; 130(21):3631-3646. PubMed ID: 39093036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
    Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
    Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E
    J Hematol Oncol; 2023 May; 16(1):44. PubMed ID: 37131217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
    Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
    Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
    George B; Kantarjian H; Jabbour E; Jain N
    Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
    Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
    Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
    Kayikci O; Akpinar S; Tekgunduz E
    Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1.
    Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ; Lee S
    Bone Marrow Transplant; 2021 Jul; 56(7):1603-1613. PubMed ID: 33526915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.